Table 1:

Patient demographics and urologic management stratified by whether samples were included or excluded from microbiome analysis.

		Excluded from Microbiome Analysis	Included in Microbiome
	Total (n=95)	(n=26)	analysis (n=69)**	p
Age (mean, SD)	56 (17)	59 (15)	55 (18)	0.31
Gender - Female	52 (55%)	13 (50%)	39 (57%)	0.57
Race				0.091
Caucasian	83 (87%)	22 (85%)	61 (88%)
Asian	2 (2%)	2 (8%)	0 (0%)
African American	3 (3%)	0 (0%)	3 (4%)
Unknown	7 (7%)	2 (8%)	5 (7%)
BMI (mean, SD)	29 (8)	28 (6)	29 (9)	0.63
Etiology of NLUTD				0.57
Spinal cord injury	43 (45%)	11 (42%)	32 (46%)
Multiple sclerosis	11 (12%)	4 (15%)	7 (10%)
Myelomeningocele	5 (5%)	2 (8%)	3 (4%)
Non-neurogenic urinary retention	10 (11%)	3 (12%)	7 (10%)
Other	30 (32%)	7 (27%)	23 (33%)
Bladder management				0.14
Intermittent catheterization	76 (80%)	23 (88%)	53 (77%)
Indwelling catheter
Urethral	15 (16%)	2 (8%)	13 (19%)
Suprapubic	3 (3%)	0 (0%)	3 (4%)
3 or more UTI over 12 months				0.49
Yes	22 (23%)	0	22
Missing	25 (27%)	25 (96%)	1 (1%)
Antibiotic Prophylaxis				0.11
Daily oral prophylaxis	7 (7%)	1 (4%)	6 (9%)
Gentamicin bladder irrigation	30 (32%)	5 (19%)	25 (36%)
None	57 (60%)	19 (73%)	38 (55%)
Both	1 (1%)	1 (4%)	0 (0%)
Non-Antibiotic Prophylaxis *
Cranberry	11 (12%)	5 (19%)	6 (9%)	0.15
D-mannose	3 (3%)	2 (8%)	1 (1%)	0.12
Methanamine	7 (7%)	1 (4%)	6 (9%)	0.42
Probiotics	8 (8%)	2 (8%)	6 (9%)	0.88
Vaginal Estrogen	2 (2%)	2 (8%)	0 (0%)	0.02
Bladder BTX-A Use	46 (48%)	8 (31%)	38 (55%)	0.035

Samples with low sequence counts (less than 1203 sequence reads per sample) (n=23) or samples that were unable to be included in microbiome assay (n=3) were excluded.

^*More than one therapy per participant may be counted

^**all participant samples within the category included in microbiome analyses, unless otherwise indicated.